Ardelyx Inc. Loss Submission Form

Company: Ardelyx Inc.

Ticker: (NASDAQ) ARDX

Deadline

Passed

Lead Plaintiff Deadline: September 28, 2021

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

Scan the QR code or click the button to join.

Join on WhatsApp

Get Updates by Email

Subscribe for email notifications.

Full Name

No spam, opt-out anytime, alert list is free.

Allegations

the likelihood that tenapanor would be approved by the Food and Drug Administration (“FDA”). Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug’s treatment effect, making it foreseeably likely that the FDA would not approve the drug.